JP2022551228A5 - - Google Patents
Info
- Publication number
- JP2022551228A5 JP2022551228A5 JP2022516163A JP2022516163A JP2022551228A5 JP 2022551228 A5 JP2022551228 A5 JP 2022551228A5 JP 2022516163 A JP2022516163 A JP 2022516163A JP 2022516163 A JP2022516163 A JP 2022516163A JP 2022551228 A5 JP2022551228 A5 JP 2022551228A5
- Authority
- JP
- Japan
- Prior art keywords
- antibiotic
- rifabutin
- item
- formulation
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025145104A JP2025176113A (ja) | 2019-09-12 | 2025-09-02 | 抗生物質併用療法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899257P | 2019-09-12 | 2019-09-12 | |
| US62/899,257 | 2019-09-12 | ||
| US201962902019P | 2019-09-18 | 2019-09-18 | |
| US62/902,019 | 2019-09-18 | ||
| US201962941160P | 2019-11-27 | 2019-11-27 | |
| US62/941,160 | 2019-11-27 | ||
| US202062977659P | 2020-02-17 | 2020-02-17 | |
| US62/977,659 | 2020-02-17 | ||
| PCT/IB2020/000645 WO2021048610A1 (en) | 2019-09-12 | 2020-08-03 | Antibiotic combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145104A Division JP2025176113A (ja) | 2019-09-12 | 2025-09-02 | 抗生物質併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551228A JP2022551228A (ja) | 2022-12-08 |
| JP2022551228A5 true JP2022551228A5 (cg-RX-API-DMAC7.html) | 2023-08-14 |
| JP7804570B2 JP7804570B2 (ja) | 2026-01-22 |
Family
ID=72432957
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516163A Active JP7804570B2 (ja) | 2019-09-12 | 2020-08-03 | 抗生物質併用療法 |
| JP2022516161A Active JP7769605B2 (ja) | 2019-09-12 | 2020-08-03 | リファブチン処置法、使用および組成物 |
| JP2025145104A Pending JP2025176113A (ja) | 2019-09-12 | 2025-09-02 | 抗生物質併用療法 |
| JP2025184422A Pending JP2026016690A (ja) | 2019-09-12 | 2025-10-31 | リファブチン処置法、使用および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516161A Active JP7769605B2 (ja) | 2019-09-12 | 2020-08-03 | リファブチン処置法、使用および組成物 |
| JP2025145104A Pending JP2025176113A (ja) | 2019-09-12 | 2025-09-02 | 抗生物質併用療法 |
| JP2025184422A Pending JP2026016690A (ja) | 2019-09-12 | 2025-10-31 | リファブチン処置法、使用および組成物 |
Country Status (17)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230364065A1 (en) | 2022-05-16 | 2023-11-16 | BioVersys AG | Antibiotic combination therapies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645508B1 (en) * | 1999-06-18 | 2003-11-11 | Jivn-Ren Chen | Stable L-ascorbic acid composition |
| CN101362067A (zh) * | 2007-08-06 | 2009-02-11 | 天津科技大学 | 一种微胶囊制备方法 |
| PL2247291T3 (pl) * | 2008-02-08 | 2019-05-31 | Red Hill Biopharma Ltd | Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit |
| MY158809A (en) | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| EA016410B1 (ru) | 2010-11-13 | 2012-04-30 | Ооо "Нпк Наносистема" | Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты) |
| WO2012106364A1 (en) | 2011-01-31 | 2012-08-09 | The Government Of The United States, As Represented By The Secretary Of The Army | Methods and compositions for treating bacterial infections with iron chelators |
| CN102178604B (zh) | 2011-03-22 | 2014-03-05 | 中国人民解放军第三0九医院 | 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球 |
| RU2472512C1 (ru) * | 2011-12-06 | 2013-01-20 | Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" | Противотуберкулезная композиция и способ ее получения |
| US10953070B2 (en) * | 2014-07-25 | 2021-03-23 | Agency For Science, Technology And Research | Antibiotic compositions for treating bacterial infections |
| EP3189154B1 (en) * | 2014-09-04 | 2023-03-22 | Labrador Diagnostics LLC | Pathogen and antimicrobial resistance testing |
| US9763996B2 (en) | 2015-01-16 | 2017-09-19 | Northern Antibiotics, Ltd. | Polymyxin derivative and uses thereof |
| WO2016178240A1 (en) * | 2015-05-04 | 2016-11-10 | Gufic Biosciences Limited | A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof |
| CN109789125B (zh) * | 2016-08-16 | 2022-10-18 | 罗切斯特大学 | 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物 |
| CA3055311A1 (en) * | 2017-02-07 | 2018-08-16 | Stc.Unm | Isotope enhanced ambroxol for long lasting autophagy induction |
| US11701346B2 (en) | 2018-11-28 | 2023-07-18 | University Of Southern California | Rifabutin for the treatment of acinetobacter baumannii |
| US20230364065A1 (en) * | 2022-05-16 | 2023-11-16 | BioVersys AG | Antibiotic combination therapies |
-
2020
- 2020-08-03 JP JP2022516163A patent/JP7804570B2/ja active Active
- 2020-08-03 EP EP20768692.4A patent/EP4028001B1/en active Active
- 2020-08-03 CA CA3154317A patent/CA3154317A1/en active Pending
- 2020-08-03 WO PCT/IB2020/000645 patent/WO2021048610A1/en not_active Ceased
- 2020-08-03 SM SM20240250T patent/SMT202400250T1/it unknown
- 2020-08-03 CN CN202080077930.0A patent/CN115052597B/zh active Active
- 2020-08-03 US US16/983,689 patent/US11351158B2/en active Active
- 2020-08-03 PH PH1/2022/550610A patent/PH12022550610A1/en unknown
- 2020-08-03 RS RS20240688A patent/RS65681B1/sr unknown
- 2020-08-03 AU AU2020347536A patent/AU2020347536B2/en active Active
- 2020-08-03 WO PCT/IB2020/000647 patent/WO2021048611A1/en not_active Ceased
- 2020-08-03 CN CN202511016208.7A patent/CN120860031A/zh active Pending
- 2020-08-03 PL PL20768692.4T patent/PL4028001T3/pl unknown
- 2020-08-03 AU AU2020344214A patent/AU2020344214B2/en active Active
- 2020-08-03 JP JP2022516161A patent/JP7769605B2/ja active Active
- 2020-08-03 CN CN202080077348.4A patent/CN114980889A/zh active Pending
- 2020-08-03 BR BR112022004645A patent/BR112022004645A2/pt unknown
- 2020-08-03 HU HUE20768692A patent/HUE066936T2/hu unknown
- 2020-08-03 HR HRP20240818TT patent/HRP20240818T1/hr unknown
- 2020-08-03 EP EP20768691.6A patent/EP4028000A1/en active Pending
- 2020-08-03 US US16/983,718 patent/US11207305B2/en active Active
- 2020-08-03 ES ES20768692T patent/ES2982067T3/es active Active
- 2020-08-03 EP EP24169078.3A patent/EP4420673A3/en active Pending
- 2020-08-03 CA CA3154129A patent/CA3154129A1/en active Pending
- 2020-08-03 KR KR1020227012086A patent/KR102991225B1/ko active Active
- 2020-08-03 BR BR112022004672A patent/BR112022004672A2/pt unknown
- 2020-08-03 MX MX2022003077A patent/MX2022003077A/es unknown
-
2021
- 2021-12-27 US US17/562,496 patent/US11766425B2/en active Active
-
2022
- 2022-06-06 US US17/833,326 patent/US11833139B2/en active Active
-
2023
- 2023-10-20 US US18/491,243 patent/US12257241B2/en active Active
-
2025
- 2025-03-24 US US19/088,662 patent/US20250281469A1/en active Pending
- 2025-09-02 JP JP2025145104A patent/JP2025176113A/ja active Pending
- 2025-10-31 JP JP2025184422A patent/JP2026016690A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matovu et al. | Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle | |
| Xun et al. | Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells | |
| JP2020023528A5 (cg-RX-API-DMAC7.html) | ||
| WO2021147235A1 (zh) | 法匹拉韦在治疗冠状病毒感染方面的应用 | |
| Sri et al. | Antiviral treatment of COVID-19: a clinical pharmacology narrative review | |
| JP2024515829A5 (cg-RX-API-DMAC7.html) | ||
| JP2022523726A5 (cg-RX-API-DMAC7.html) | ||
| JP2022537047A5 (cg-RX-API-DMAC7.html) | ||
| JP2022514759A5 (cg-RX-API-DMAC7.html) | ||
| JP2013503880A5 (cg-RX-API-DMAC7.html) | ||
| PH12022552516A1 (en) | Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease | |
| Qu et al. | COVID-19: the epidemiology and treatment | |
| Ferreira et al. | COVID-19: small-molecule clinical trials landscape | |
| Rodríguez et al. | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection | |
| JP2022519007A5 (cg-RX-API-DMAC7.html) | ||
| JP2025176113A5 (cg-RX-API-DMAC7.html) | ||
| CN104039955A (zh) | 新噬菌体 | |
| JPWO2023210732A5 (cg-RX-API-DMAC7.html) | ||
| Irie et al. | Treatment of coronavirus disease 2019 with saikatsugekito: a case series | |
| Dang et al. | Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events | |
| MX2025012741A (es) | Composiciones farmaceuticas orales | |
| Ranjan et al. | Preclinical development of inhalable D-cycloserine and ethionamide to overcome pharmacokinetic interaction and enhance efficacy against Mycobacterium tuberculosis | |
| Wang et al. | Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains | |
| JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 | |
| JP2022526643A5 (cg-RX-API-DMAC7.html) |